These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31262915)

  • 1. Clinical Characteristics Associated With Lenvatinib-induced Fistula and Tumor-related Bleeding in Patients With Thyroid Cancer.
    Staub Y; Nishiyama A; Suga Y; Fujita M; Matsushita R; Yano S
    Anticancer Res; 2019 Jul; 39(7):3871-3878. PubMed ID: 31262915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding.
    Resteghini C; Locati LD; Bossi P; Bergamini C; Guzzo M; Licitra L
    Ann Oncol; 2017 Sep; 28(9):2321-2322. PubMed ID: 28911079
    [No Abstract]   [Full Text] [Related]  

  • 5. Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma.
    Masaki C; Sugino K; Saito N; Saito Y; Tanaka T; Ogimi Y; Maeda T; Osaku T; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
    Endocr J; 2017 Aug; 64(8):819-826. PubMed ID: 28659544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug safety evaluation of lenvatinib for thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas.
    Uchida-Kobayashi S; Kageyama K; Yamamoto A; Ikenaga H; Yoshida K; Kotani K; Kimura K; Odagiri N; Hagihara A; Fujii H; Enomoto M; Tamori A; Kubo S; Miki Y; Kawada N
    Oncology; 2021; 99(3):186-191. PubMed ID: 33032274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
    Giani C; Valerio L; Bongiovanni A; Durante C; Grani G; Ibrahim T; Mariotti S; Massa M; Pani F; Pellegriti G; Porcelli T; Salvatore D; Tavarelli M; Torlontano M; Locati L; Molinaro E; Elisei R
    Thyroid; 2021 Feb; 31(2):224-232. PubMed ID: 32907501
    [No Abstract]   [Full Text] [Related]  

  • 10. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
    Ye X; Zhu Y; Cai J
    J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
    Wirth LJ; Durante C; Topliss DJ; Winquist E; Robenshtok E; Iwasaki H; Luster M; Elisei R; Leboulleux S; Tahara M
    Oncologist; 2022 Jul; 27(7):565-572. PubMed ID: 35482606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer].
    Yamazaki H; Shimizu S; Iwasaki H; Yoshida T; Suganuma N; Yamanaka T; Kojima I; Masudo K; Toda S; Nakayama H; Masuda M
    Gan To Kagaku Ryoho; 2017 Aug; 44(8):695-697. PubMed ID: 28860443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.
    Date E; Okamoto K; Fumita S; Kaneda H
    Invest New Drugs; 2018 Apr; 36(2):350-353. PubMed ID: 29018997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
    Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
    Nagahama M; Ozeki T; Suzuki A; Sugino K; Niioka T; Ito K; Miura M
    Med Oncol; 2019 Mar; 36(5):39. PubMed ID: 30919115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
    Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
    Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hand-foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer.
    Minaldi E; Cappagli V; Lorusso L; Valerio L; Giani C; Viglione M; Agate L; Molinaro E; Matrone A; Elisei R
    Eur Thyroid J; 2024 Aug; 13(4):. PubMed ID: 38954633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
    Tori M; Shimo T
    BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.
    Osawa Y; Gozawa R; Koyama K; Nakayama T; Sagoh T; Sunaga H
    Intern Med; 2018 Apr; 57(7):1015-1019. PubMed ID: 29225265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.